Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Open-Label Pharmacokinetics and Safety Study of rFVIIIFc (Efmoroctocog alfa) at Different Manufacturing Scales
2014-003895-21Phase 3
- Sponsor
- Biogen
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efmoroctocog alfa in hemophilia A (2 arms), sponsored by Biogen. Primary endpoint: Pharmacokinetic parameters of rFVIIIFc (primary).
02
Drugs
efmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2014-003895-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003895-21.